MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $81.43 Average PT from Brokerages

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $81.43.

Several equities analysts have recently issued reports on MLTX shares. Wedbush reiterated an “outperform” rating and issued a $73.00 price target (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of MoonLake Immunotherapeutics in a research note on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research note on Friday, January 10th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MLTX. US Bancorp DE acquired a new stake in MoonLake Immunotherapeutics in the third quarter valued at $44,000. Quarry LP raised its holdings in MoonLake Immunotherapeutics by 172.7% during the 2nd quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $132,000 after purchasing an additional 1,900 shares during the last quarter. Barclays PLC lifted its position in shares of MoonLake Immunotherapeutics by 1,269.2% in the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after purchasing an additional 5,229 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of MoonLake Immunotherapeutics by 26.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after purchasing an additional 2,700 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth $706,000. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ:MLTX opened at $46.50 on Friday. The business’s 50 day simple moving average is $52.13 and its 200 day simple moving average is $49.02. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $64.98. The company has a market capitalization of $2.97 billion, a P/E ratio of -36.05 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same quarter in the previous year, the company earned ($0.18) EPS. On average, sell-side analysts anticipate that MoonLake Immunotherapeutics will post -1.75 EPS for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.